2022
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. CardioVascular And Interventional Radiology 2022, 45: 405-412. PMID: 35119481, PMCID: PMC8940827, DOI: 10.1007/s00270-021-03031-9.Peer-Reviewed Original ResearchConceptsBlinded independent central reviewIntermediate-stage hepatocellular carcinomaDisease control rateObjective response rateProgression-free survivalDuration of responseHepatocellular carcinomaCurative treatmentRECIST 1.1Primary endpointClinical benefitControl rateEastern Cooperative Oncology Group performance status 0Response rateChild-Pugh class ARandomized phase 3 studyDual primary endpointsOverall survival eventsPerformance status 0Previous systemic treatmentPD-1 inhibitorsPortal vein thrombosisPhase 3 studyResponse Evaluation CriteriaSolid Tumors 1.1
2020
Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update
Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers 2020, 12: 791. PMID: 32224882, PMCID: PMC7226474, DOI: 10.3390/cancers12040791.Peer-Reviewed Original ResearchStage hepatocellular carcinomaSelective internal radiotherapyAdvanced-stage hepatocellular carcinomaTrans-arterial chemoembolizationHepatocellular carcinomaRecent large prospective trialsSimilar disease control rateManagement of HCCEarly-stage hepatocellular carcinomaStage of HCCDisease control rateSystemic treatment optionsLarge prospective trialsLocal disease controlCancer-related morbidityArterial therapyProspective trialImproved tolerabilityPalliative optionControl rateTreatment optionsTherapeutic strategiesDisease controlInternal radiotherapyTolerability